Tag: Biocon
US-FDA accepts Mylan & Biocon’s joint application on biosimilar Trastuzumab
While the Biologics License Application (BLA) for MYL-1401O has been accepted by the United States FDA, if approved, it has the potential to be the first biosimilar Trastuzumab in the US....
Dr Kiran Shaw to debut at Serendipity Arts Festival 2016
As she debuts at the Art & Science Exhibition, Kiran M Shaw is one of the many patrons that have come on board.....
Delhi set to host ABLE’s BioEconomy Conclave 2016
The Association of Biotechnology Led Enterprises (ABLE) is organizing the BioEconomy India Conclave 2016 on November 29-30 at India Habitat Centre, Delhi....
Mylan & Biocon announce first joint USFDA submission for biosimilar, Trastuzumab
Besides being an important milestone of Biocon and Mylan's joint global biosimilars program, the first biosimilar trastuzumab if approved by the top regulator.....
Syngene registers Rs 319 crore as revenue in Q2
Syngene International, Biocon’s contract research arm has registered a 22 per cent increase in revenue......
Biocon’s net profit jumps to Rs 146.7 cr in 2nd quarter...
With consolidated net profit of Rs 146.7 crore, the biotechnology giant, Biocon has shown good performance for the second quarter of financial year 2016-17....
Dr Kas Subramanian joins Syngene International
Having headed the R&D division at the Strand Life Sciences, Dr Kalyanasundaram Subramanian will now spearhead the bioinformatics initiative....
Biocon registers strong performance, profits up by 17%
Biocon in the first quarter of the financial year 2016-17, has reported the revenues of Rs 952 crore; net profit up by 17 percent at Rs 147 crore ....
India’s first siRNA drug to treat rare eye disease soon
The elderly patients afflicted by a rare eye disease, NAION (non-arteritic ischemic optic neuropathy) that leads...
Syngene delivers sustained growth in its Quarter 4 results
The company's revenue grows 31 percent to Rs 334 crore and EBITA is up by 23 percent to Rs 106 crore...